Polygenic contributions to lithium augmentation outcomes in antidepressant non-responders with unipolar depression.

ABSTRACT:

Objective

Lithium augmentation (LA) is an effective treatment for patients with major depression after inadequate antidepressant response, but therapeutic outcomes vary considerably between individuals. Molecular studies could yield novel insights into treatment prediction to enable personalized therapy choices. Here, we investigated the effects of polygenic risk scores (PRS) for schizophrenia (SCZ), major depressive disorder (MDD), and bipolar disorder (BIP) on clinical outcomes following LA.

Methods

Recent GWAS summary statistics were used to construct disorder-specific PRS in lithium-augmented MDD patients who participated in a prospective study after poor response to at least one antidepressant drug. Depressive symptoms were assessed for four weeks or longer using the Ha

SUBMITTER: Kraft J 

PROVIDER: S-EPMC11838996 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature